Virus-like particles as vaccines for paramyxovirus
AssigneeUniversity of Massachusetts Medical School
InventorsTrudy Morrison, Homer Pantua
Life of this patent
Estimating the term…
Abstract
The present invention discloses the method of making and using a novel, non-infective, paramyxovirus vaccine. Paramyxovirus structural proteins within a virus-like particle (VLP) comprise one example of such a vaccine. It is observed that the presence of matrix protein, alone, is sufficient and necessary to provide an effective VLP release. Co-expression of four paramyxovirus structural proteins, however, result in the release of non-infective VLPs with densities and efficiencies of release similar to that of infective particles. Representative diseases wherein a VLP vaccine might be useful include, but are not limited to, Newcastle disease, measles, respiratory syncytial virus infection, and parainfluenza 3 virus infection.
Claims15
A method, comprising;
- a) providing,
- i) an expression vector comprising DNA sequences encoding a Newcastle disease matrix protein;
- ii) a cell capable of being transfected by said vector;
- b) transfecting said cell with said vector under conditions such that Newcastle disease virus-like particles are generated.
A method, comprising;
- a) providing,
- i) a vaccine comprising Newcastle disease virus-like particles, said particles comprising a Newcastle disease viral matrix protein;
- ii) a host susceptible to Newcastle disease;
- b) immunizing said host with said vaccine under conditions such that antibodies directed to said virus-like particle are produced.
A vaccine comprising Newcastle disease virus-like particles, said particles comprising a Newcastle disease viral matrix protein.
Dependencies are inferred from the claim text.